Upcoming Syndicated P&T Session & Webcast
Psoriasis: Syndicated Session
On June 18th, observe a syndicated, simulated P&T session focused on the approvals of spesolimab, deucravacitinib, and tapinarof, and how these agents will be managed for psoriasis.
MMIT’s syndicated P&T Perspectives session provides qualitative and tangible feedback through a simulated P&T session that informs your brand’s strategy and enables you to understand how your product and/or competitor’s product will fare in an actual P&T Committee review.
Use P&T Perspectives to:
- See how a simulated large, national multi-state health plan will review new to market entrants through a 90-minute live-streaming session with 15-minute Q&A
- Understand how health plans are running cost analyses on your brand or competitors
- Learn from autonomously developed session material and clinical dossiers to inform brand strategy and messaging
View a clip from a recent P&T session.